![ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business](https://mms.businesswire.com/media/20180914005613/en/678526/5/AJOVY+Image.jpg)
ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business
![Teva Pharmaceuticals Successfully Defends Against Allegations of Patent Infringement | Parsippany Focus Teva Pharmaceuticals Successfully Defends Against Allegations of Patent Infringement | Parsippany Focus](https://i0.wp.com/parsippanyfocus.com/uploadedmedia/2024/01/teva.jpg?fit=720%2C480&ssl=1)
Teva Pharmaceuticals Successfully Defends Against Allegations of Patent Infringement | Parsippany Focus
![Shlomo Yanai, CEO of Israeli drug maker Teva Pharmaceutical Industries Ltd.'s announces the acquisition of German generic drug maker Ratiopharm during a press conference in Cologne, western Germany, on Thursday, March 18, Shlomo Yanai, CEO of Israeli drug maker Teva Pharmaceutical Industries Ltd.'s announces the acquisition of German generic drug maker Ratiopharm during a press conference in Cologne, western Germany, on Thursday, March 18,](https://l450v.alamy.com/450v/2p7j9gn/shlomo-yanai-ceo-of-israeli-drug-maker-teva-pharmaceutical-industries-ltds-announces-the-acquisition-of-german-generic-drug-maker-ratiopharm-during-a-press-conference-in-cologne-western-germany-on-thursday-march-18-2010-teva-has-beaten-out-rivals-to-acquire-ratiopharm-in-a-deal-worth-some-36-billion-euro-or-nearly-5-billion-us-dollar-ap-photodapdroberto-pfeil-2p7j9gn.jpg)
Shlomo Yanai, CEO of Israeli drug maker Teva Pharmaceutical Industries Ltd.'s announces the acquisition of German generic drug maker Ratiopharm during a press conference in Cologne, western Germany, on Thursday, March 18,
![Teva to pay $225 million fine and divest cholesterol drug to settle price-fixing charges | CNN Business Teva to pay $225 million fine and divest cholesterol drug to settle price-fixing charges | CNN Business](https://media.cnn.com/api/v1/images/stellar/prod/230821162715-teva-pharmaceuticals-file-restricted.jpg?c=original)
Teva to pay $225 million fine and divest cholesterol drug to settle price-fixing charges | CNN Business
![Teva Pharmaceuticals on X: "Teva unveils new world class #pharma facility at #Mumbai R&D center: https://t.co/s0LOWejMwH https://t.co/jKjOxoAaGc" / X Teva Pharmaceuticals on X: "Teva unveils new world class #pharma facility at #Mumbai R&D center: https://t.co/s0LOWejMwH https://t.co/jKjOxoAaGc" / X](https://pbs.twimg.com/media/DjDFwiiUUAAgYTs.jpg)
Teva Pharmaceuticals on X: "Teva unveils new world class #pharma facility at #Mumbai R&D center: https://t.co/s0LOWejMwH https://t.co/jKjOxoAaGc" / X
![Award of Merit Manufacturing: TEVA Biologics Manufacturing Facility | 2018-10-16 | Engineering News-Record Award of Merit Manufacturing: TEVA Biologics Manufacturing Facility | 2018-10-16 | Engineering News-Record](https://www.enr.com/ext/resources/Issues/MidAtlantic_Issues/2018/10-October/22-Oct/teva-pilot-plant01.jpg?height=635&t=1539627719&width=1200)